Clinical Trials on Mixed Dyslipidaemia in Finland

Total 195 results

GlaxoSmithKline

Completed

GW501516 In Subjects Who Have Low Level Of High-Density Lipoprotein Cholesterol

Dyslipidaemia | Dyslipidaemias

Germany, Estonia, Belgium, France, Netherlands, Denmark, Portugal, Norway, Sweden, Lithuania, Finland
NeuroBo Pharmaceuticals Inc.

Completed

A 12-Week Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia (INDIGO-1)

Severe Hypertriglyceridemia | Mixed Dyslipidaemia

United States, Canada
Abbott

Completed

An Open-Label Study to Compare the Lipid Effects of Niacin ER and Simvastatin (NS) to Atorvastatin in Subjects With Hyperlipidemia or Mixed Dyslipidemia (SUPREME) (SUPREME)

Hyperlipidemia | Mixed Dyslipidemia

United States
Amgen

Completed

Evaluation of Evolocumab (AMG 145) Efficacy in Diabetic Adults With Hypercholesterolemia/Mixed Dyslipidemia (BANTING)

Type 2 Diabetes | Hypercholesterolemia | Mixed Dyslipidemia

United States, Italy, Belgium, Spain, Canada, Poland, Mexico
Marja-Riitta Taskinen
Göteborg University

Enrolling by invitation

Genetic Pathways Leading to Fatty Liver and Atherogenic Dyslipidemia (VARKIN)

Insulin Resistance | Non-alcoholic Fatty Liver | Atherogenic Dyslipidemia

Finland, Sweden
Abbott

Completed

Safety and Efficacy Study Comparing ABT-335 Coadministered With Atorvastatin and Ezetimibe to Atorvastatin Coadministered With Ezetimibe in Subjects With Multiple Abnormal Lipid (Fat) Levels in the Blood

Dyslipidemias | Coronary Heart Disease | Mixed Dyslipidemia | Combined (Atherogenic) Dyslipidemia

United States
Tampere University
Tampere University Hospital; Sitra, the Finnish Innovation Fund

Completed

Get-a-Grip Lifestyle Management Programme

Hypertension | Diabetes | Dyslipidemias | Overweight and Obesity

Finland
Marjukka Kolehmainen
VTT Technical Research Centre, Finland

Completed

The Health Effect of Diet Rich in Nordic Berries (Berry)

Metabolic Syndrome | Dyslipidemia | Impaired Glucose Tolerance | Low-grade Inflammation

Finland
Kowa Research Europe

Completed

Study to Compare the Efficacy and Safety of Pitavastatin and Simvastatin

Dyslipidemia | Hypercholesterolemia

Finland, Italy, Norway, Russian Federation, United Kingdom
Sanofi

Terminated

European Trial About Effect of RimoNabant on Abdominal Obese Patients With dysLipidemia (ETERNAL)

Obesity | Dyslipidemias

Germany, Netherlands, Turkey, Slovakia, United Kingdom, Finland, Hungary, Ireland, Italy, Norway, Greece, Sweden, Czech Republic, Portugal, Switzerland
Solvay Pharmaceuticals

Terminated

Fenofibrate and Metformin Insulin Sensitivity in Type 2 Diabetics Study

Type 2 Diabetes | Dyslipidemia

Finland, Ireland, Italy
Takeda

Completed

Efficacy of Lapaquistat Acetate and Simvastatin in Subjects With Primary Dyslipidemia.

Hypercholesterolemia

Poland, United Kingdom, Germany, South Africa, Finland, Estonia, Czech Republic
Bristol-Myers Squibb

Completed

Safety Study of BMS-770767 in Subjects With Hypercholesterolemia

Dyslipidemia

Canada, Australia, United States
Takeda

Completed

Effect of Lapaquistat Acetate on Blood Cholesterol Levels in Subjects With Elevated Cholesterol

Dyslipidemia

United States
Providence VA Medical Center
Sandra A. Daugherty Foundation

Completed

Multi-Targeted Cardiac Risk Intervention in Type 2 Diabetes

Hypertension | Diabetes | Dyslipidemia

United States
Arrowhead Pharmaceuticals

Active, not recruiting

Study of ARO-APOC3 in Adults With Dyslipidemia

Dyslipidemias

United States, Australia, Canada, Poland, Netherlands, New Zealand, Hungary
Amgen

Completed

Evaluating PCSK9 Binding antiBody Influence oN coGnitive HeAlth in High cardiovascUlar Risk Subjects (EBBINGHAUS)

Dyslipidemia

United States, Belgium, Denmark, Finland, France, Italy, Spain, Hungary, Poland, Germany, Czechia, Turkey, United Kingdom, Malaysia, Australia, Hong Kong, New Zealand, Canada, South Africa, Greece, Portugal, Netherlands, Russian Federation and more
Sanofi

Completed

Obese Patients With Untreated Dyslipidemias (RIO-Lipids)

Obesity | Dyslipidemia

United States, Canada, Australia, Italy, Spain, Sweden, Switzerland, Finland
Amgen

Completed

Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk Open-label Extension (FOURIER OLE)

Dyslipidemia

United States, Poland, Czechia, Hungary, Russian Federation, Ukraine, Slovakia
Kowa Research Europe

Completed

Long-Term Extension Study of Pitavastatin in Patients With Primary Hypercholesterolemia or Combined Dyslipidemia

Dyslipidemia | Hypercholesterolemia

Spain, Denmark, India, Israel, Sweden, Finland, Germany, Italy, Netherlands, Norway, Poland, Russian Federation, United Kingdom
Raisio Group

Active, not recruiting

Lipid Lowering Effect of Plant Stanol Ester in a Drinkable Non-dairy Product

Hypercholesterolemia

Finland
Marjukka Kolehmainen
Raisio Plc

Completed

Effect of High Stanol Ester Dose on Serum Lipids, Carotenoids and Fat-soluble Vitamins (maxsta)

Hypercholesterolemia

Finland
Raisio Group

Completed

Lipid Lowering Effect of Plant Stanol Ester in a Spoonable Non-dairy Product

Hypercholesterolemia

Finland
Oy Foodfiles Ltd

Completed

Effect of Plant Stanols on Cholesterol Absorption (DOSE)

Hypercholesterolemia

Finland
Amgen

Completed

Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk (FOURIER)

Dyslipidemia

United States, Austria, Belgium, Canada, Denmark, Finland, France, Germany, Italy, Netherlands, Spain, Sweden, United Kingdom, Czechia, Hungary, Taiwan, Colombia, Poland, Russian Federation, Switzerland, Korea, Republic of, Mexico, ... and more
Pfizer

Terminated

A Clinical Trial Comparing Torcetrapib/Atorvastatin To Simvastatin In Subjects With High Cholesterol (A5091031).

Dyslipidemia | Hypercholesterolemia | Hyperlipidemia

United States
Pfizer

Completed

A Clinical Trial Comparing Torcetrapib/Atorvastatin To Simvastatin In Subjects With High Cholesterol.

Dyslipidemia | Hypercholesterolemia | Hyperlipidemia

United States
Kowa Research Europe

Completed

Study to Compare the Efficacy of Pitavastatin With That of Atorvastatin in Lowering Cholesterol Levels

Dyslipidemia | Primary Hypercholesterolemia

Spain, Denmark, India, Israel, Sweden, Finland, Germany, Italy, Netherlands, Norway, Poland, Russian Federation, United Kingdom
Pfizer

Terminated

A Clinical Trial Comparing Torcetrapib/Atorvastatin to Ezetimibe/Simvastatin In Subjects With A Cholesterol Disorder.

Dyslipidemia | Hyperlipidemia

United States
Kowa Research Institute, Inc.

Withdrawn

Efficacy & Long-term Safety Comparison Study of NK-104-CR & Livalo® IR With Primary Hyperlipidemia or Mixed Dyslipidemia

Dyslipidemia | Hyperlipidemia

United States
Pfizer

Completed

Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects With Primary Hyperlipidemia or Mixed Dyslipidemia At Risk Of Cardiovascular Events (SPIRE-LL)

Hyperlipidemia

Finland, Netherlands, United States, Canada, Sweden, Korea, Republic of, Singapore, Czechia, Poland, United Kingdom, Puerto Rico, Norway
Abbott

Completed

Study to Evaluate the EFFECTS of Acetylsalicylic Acid (ASA) on Niaspan®-Induced Flushing in Subjects With Dyslipidemia (ASA EFFECTS)

Dyslipidemia

United States
Sanofi
Regeneron Pharmaceuticals

Completed

Efficacy and Safety of Alirocumab Versus Usual Care on Top of Maximally Tolerated Statin Therapy in Patients With Type 2 Diabetes and Mixed Dyslipidemia (ODYSSEY DM-Dyslipidemia)

Dyslipidemia

United States, Australia, Brazil, Finland, Germany, Israel, Italy, Kuwait, Lebanon, Norway, Sweden, Switzerland, Turkey, United Arab Emirates, United Kingdom
Pfizer

Completed

Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects With Hyperlipidemia or Mixed Dyslipidemia at Risk of Cardiovascular Events (SPIRE-LDL)

Hyperlipidemia

United States, Spain, Taiwan, United Kingdom, Canada, Mexico, France, Hungary, Lithuania, Colombia, Romania, Russian Federation
Solvay Pharmaceuticals

Terminated

Fenofibrate and Metformin Fixed Combination vs Rosiglitazone - FAME ROSI

Dyslipidemia | Glucose Metabolism Disorder

Poland, Croatia, Finland, France, Germany, Netherlands, Romania, Ukraine
Providence VA Medical Center
Rhode Island Foundation

Completed

Combined Behavioral and Pharmacological Intervention for Cardiovascular Risk Reduction in Diabetic Patients

Hypertension | Diabetes | Dyslipidemia | Coronary Arteriosclerosis

United States
Providence VA Medical Center
Merck Sharp & Dohme LLC

Completed

Strategies to Maintain Cardiac Risk Control After Discharge From Cardiovascular Risk Reduction Clinic

Hypertension | Diabetes | Dyslipidemia | Coronary Atherosclerosis

United States
University of Helsinki
University of Eastern Finland

Unknown

Dietary Phytosterols and Human Aortic Valve

Atherosclerosis | Hypercholesterolemia

Finland
Pfizer's Upjohn has merged with Mylan to form Viatris...

Completed

A Multi-Risk Factor Strategy vs a Guideline-Based Approach in Achieving Blood Pressure and Lipid Goals in Hypertensives at Extra Risk (TOGETHER)

Hypertension | Dyslipidemia

United States
Amgen

Completed

Getting to an Improved Understanding of Low-Density Lipoprotein Cholesterol and Dyslipidemia Management (GOULD) a Registry of High Cardiovascular Risk Subjects in the United States

Dyslipidemia | Medical Conditions to be Studied | ASCVD Management

United States
Newcastle University
Assistance Publique - Hôpitaux de Paris; Medical University of Vienna; University... and other collaborators

Recruiting

The European NAFLD Registry

Cardiovascular Diseases | Hypertension | Obesity | Hepatocellular Carcinoma | Type 2 Diabetes | NAFLD | Fibrosis, Liver | NASH - Nonalcoholic Steatohepatitis | Dyslipidaemia | NASH | Steatosis of Liver | Other Associated Comorbidities

Netherlands, Germany, United Kingdom, Finland, Belgium, Greece, Italy, Sweden, Portugal, Spain, France, Switzerland
Pfizer's Upjohn has merged with Mylan to form Viatris...

Completed

Open Label Study To Assess The Effectiveness Of Amlodipine-Atorvastatin Combination In Hypertension And Dyslipidemia. (JEWEL II)

Hypertension | Hyperlipidemia

Greece, Austria, Finland, Italy, Hungary, Belgium, Spain, Ireland, Portugal, Slovenia, Switzerland
Pfizer's Upjohn has merged with Mylan to form Viatris...

Completed

Open Label Study Assessing Effectiveness Of Amlodipine/Atorvastatin In Subjects With Hypertension and Dyslipidaemia (JEWEL I)

Hypertension | Dyslipidemia

Canada, United Kingdom
Coxa, Hospital for Joint Replacement
Tampere University; Tampere University Hospital

Terminated

Glucose Metabolism Disorders and Metabolic Syndrome Before and After Primary Hip and Knee Replacement (HyTe-2)

Hyperglycemia | Hypercholesterolemia | Knee Replacement | Hip Replacement | Persistent Postoperative Pain

Finland
University of Turku
University of Eastern Finland

Active, not recruiting

OAT-GUT-BRAIN: Effects of Oats and Rice on Comprehensive Health of Metabolically Challenged Individuals

Overweight and Obesity | High Blood Pressure | High Cholesterol/Hyperlipidemia

Finland
Pfizer

Terminated

Carotid B-mode Ultrasound Study to Compare Anti-Atherosclerotic Effect of Torcetrapib/Atorvastatin to Atorvastatin. (RADIANCE 2)

Mixed Hyperlipidemia

United States, Canada, Czech Republic, Finland, France, Netherlands
Marja-Riitta Taskinen
Lund University; Sahlgrenska University Hospital, Sweden; Laval University; University...

Completed

Fructose Consumption and Metabolic Dysregulation

Hypertriglyceridemia | Central Obesity

Canada, Finland, Italy, Sweden
University of Oulu
Oulu University Hospital; Juho Vainio Foundation; Yrjo Jahnsson Foundation

Completed

The Effect of CBT- Based Weight Loss Program on Obesity (CognObe)

Obesity | Diabetes Mellitus, Type 2 | Anhedonia | Hypercholesterolemia

Finland
Sanofi
Regeneron Pharmaceuticals

Completed

Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Ezetimibe in Patients With Hypercholesterolemia (ODYSSEY MONO)

Hypercholesterolemia

United States, Belgium, Finland, Netherlands
Kowa Research Institute, Inc.
Brigham and Women's Hospital

Terminated

Pemafibrate to Reduce Cardiovascular OutcoMes by Reducing Triglycerides IN patiENts With diabeTes (PROMINENT) (PROMINENT)

Dyslipidemia | Type2 Diabetes

United States, Spain, Canada, Hungary, Netherlands, Brazil, Bulgaria, Poland, Israel, Russian Federation, Ukraine, Denmark, Czechia, South Africa, Argentina, Mexico, United Kingdom, Romania, Germany, India, Slovakia, Japan, Colombia, ... and more

Clinical Trials on Mixed Dyslipidaemia in Finland

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in United States

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations